Drug Index

Everolimus

 
print

Mechanism :

Everolimus is a macrolide immunosuppressant and a mechanistic target of rapamycin (mTOR) inhibitor which has antiproliferative and antiangiogenic properties, and also reduces lipoma volume in patients with angiomyolipoma.
Reduces protein synthesis and cell proliferation by binding to the FK binding protein-12 (FKBP-12), an intracellular protein, to form a complex that inhibits activation of mTOR) serine-threonine kinase activity.


Indication :

• Tuberous sclerosis complex-associated partial-onset seizures

• Tuberous sclerosis complex-associated subependymal giant cell astrocytoma

• Neuroendocrine tumors: Progressive pancreatic neuroendocrine tumors (PNET)

• Renal cell carcinoma

• Liver and renal transplantation


Contraindications :

Clinically significant hypersensitivity to everolimus, other rapamycin derivatives, or any component of the formulation.


Dosing :

Tuberous sclerosis complex-associated partial-onset seizures:

Oral: Initial 5 mg/m2 once daily; continue until disease progression or unacceptable toxicity.

Tuberous sclerosis complex-associated subependymal giant cell astrocytoma:

Oral: 4.5 mg/m2 once daily; continue until disease progression or unacceptable toxicity.


Adverse Effect :

Stomatitis, constipation, infections, asthenia, fatigue, cough, diarrhea, rash, anemia, nausea, anorexia, edema, peripheral, dyspnea, pyrexia, vomiting, headache, epistaxis, decreased lymphocytes, increased glucose, pneumonitis, pruritus, dry skin, menstrual irregularities, hypertension, hemorrhage, tachycardia, congenital heart failure.


Interaction :

Angiotensin-Converting Enzyme Inhibitors: Everolimus may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors.
Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents.
CYP3A4 Inducers: May decrease the serum concentration of Everolimus.
CYP3A4 Inhibitors: May increase the serum concentration of Everolimus.
Efavirenz: May decrease the serum concentration of Everolimus.
Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.



Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnknown dialysability. Dose as in normal renal function
HDUnknown dialysability. Dose as in normal renal function
HDF/High fluxUnknown dialysability. Dose as in normal renal function
CAV/VVHDUnknown dialysability. Dose as in normal renal function

Hepatic Dose :

Tuberous sclerosis complex (TSC)-associated subependymal giant cell astrocytoma (SEGA) or partial-onset seizures:
Mild to moderate hepatic impairment: Dosing should be based on therapeutic drug monitoring every 1-2 weeks after initiation maintaining target trough concentration 5 to 15 ng/mL. Adjust the dose using the equation: new dose = current dose x (target concentration divided by current concentration). The maximum dose increment at any titration must not exceed 5 mg.
Severe hepatic impairment: Reduce initial dose to 2.5 mg/sqm once daily. Subsequent dosing is based on therapeutic drug monitoring 2 weeks after initiation maintaining target trough concentration 5 to 15 ng/mL.

Renal and liver transplant rejection prophylaxis
Mild hepatic impairment: Reduce the initial daily dosage by approximately one-third; adjust dose as per trough levels maintaining target trough concentration of 3 to 8 ng/mL.
Moderate and Severe hepatic impairment: Reduce the initial daily dosage by approximately one-half; adjust dose as per trough levels maintaining target trough concentration of 3 to 8 ng/mL.
06/24/2020 06:09:36 Everolimus
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0